/Investor DB

Illumina Ventures — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

NuCicernucicer.cominOct 2022

NuCicer develops improved crop varieties through selective breeding, starting with high-protein chickpeas designed for better nutrition.

AgTechAI & Machine LearningFoodTechDavis, US

Kathryn Cook(Executive Officer, Director)inDouglas Cook(Executive Officer, Director)

BoardPaimun Amini(Director)inJerry Steiner(Director)inCarsten Boers(Director)in

Co-investorsBetter Ventures Central LlcBlue Horizon CorporationLever VCRhapsody Venture PartnersStray Dog CapitalTrellis Road I Fund AB+1 more

Protillion Biosciencesprotillion.cominSeries A · Dec 2022 · $18M

Protillion Biosciences develops platform technology for antibody engineering and drug discovery.

AI & Machine LearningBiotechDeep TechCarlsbad, US

Curtis Layton(CEO/Co-Founder)inDavid Walt(Co-Founder)inWill Greenleaf(Co-Founder)inRobert Hollingsworth(Chief Scientific Officer)in

BoardSean Kendall(Director)inMalek Faham(Director)in

Co-investorsARCH Venture PartnersMerck Global Health Innovation FundMSD Global Health Innovation Fund

Rebus Biosystemsrebusbio.cominOct 2022

Santa Clara, US

Jekwan Ryu(Executive Officer, Director)Ronald M. Cook(Director)Eric Williams(Executive Officer)Tae Hoon Nahm(Director)

BoardTom Willis(Director, Executive Officer)in

Co-investorsWestern Technology Investment

Sherlock Biosciencessherlock.bioin𝕏Mar 2022 · $80M

The company develops diagnostics and biological sample collection devices, including a rapid sickle-cell test, supporting infectious disease detection and genomic, metabolomic, and microbiome research.

BiotechHealthtechMedical DevicesCambridge, US

Rahul Dhanda(Executive Officer, Director)inJames Collins(Director)David Walt(Director)in

BoardIssi Rozen(Director)in

Co-investorsCatalio Capital Management, LPGaingelsCatalio Capital ManagementGood VenturesGV (Google Ventures)Northpond Ventures+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.